Savara Inc.

SVRA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$4.73-1.87%

2026-11-02

Financials

Valuation Metrics

Savara Inc.'s Market Cap is $969M. At end of 2025 it was $1.34B. Ranked #2413 of 3,114 in US market (top 77%), #982 of 1,472 on NASDAQ (top 67%), #178 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$969M	US#2,413/3,114 Sec#178/265
Revenue	$0.00	US#2,862/3,114 Sec#193/265
Net Income	$-139M	US—/3,114 Sec—/265
Total Assets	$192M	US#2,991/3,114 Sec#245/265
Net Assets	$144M	US#2,746/3,114 Sec#204/265
Employees	70	US#2,664/3,114 Sec#194/265
Value
P/B	6.75x	US#2,441/3,114 Sec#171/265
FCF Yield	-11.42%	US—/3,114 Sec—/265
Profitability
ROE	-96.97%	US#2,779/3,114 Sec#200/265
ROA	-72.50%	US#3,032/3,114 Sec#242/265
Financial Health
Debt Ratio	33.74%	US#383/3,114 Sec#113/265
Total Debt	$30M	US#2,687/3,114 Sec#175/265
FCF	$-111M	US#2,653/3,114 Sec#153/265
Cash	$42M	US#2,646/3,114 Sec#234/265
Current Ratio	10.13x	US#245/3,114 Sec#76/265
Performance
1Y Return	13.98%	US#1,361/3,114 Sec#118/265
1M Return	-1.66%	US#1,942/3,114 Sec#140/265
From 52W High	-32.52%	US#1,978/3,114 Sec#123/265
1Y MDD	-39.19%	US#1,894/3,114 Sec#118/265
Trading
Volume	1,420,629 shares	US#514/3,114 Sec#45/265
Trading Value	$7M	US#1,956/3,114 Sec#154/265
Per Share
EPS	$-0.68	US—/3,114 Sec—/265
BPS	$0.70	US#2,729/3,114 Sec#209/265

Company Info

CEO Matthew Pauls

Employees 70

HQ Yardley, US

Website https://www.savarapharma.com

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.